This clinical trial demonstrated that the anti-HER2 DNA vaccine was safe, well tolerated after i.m. and intradermal administration and could induce long-lasting cellular and humoral immune responses against HER2 in patients with advanced breast cancer (Norell et al., 2010). The gene discussed is ERBB2; the disease is breast carcinoma.